Eardream Data Collection in Colombia Supported by ADDF

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Data collection based on this study will allow us to collect neurophysiological and cognitive data collected from in-ear EEG recordings of the Autosomal dominant alzheimer's disease population in Colombia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Eardream Data Collection in Switzerland Supported by ADDF

NCT05320471

Healthy Aging

UNKNOWN

Investigating Electroencephalographic Predictors of Default Mode Network Anticorrelation in Healthy Adults

NCT05592600

Healthy

COMPLETED NA

Links Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG

NCT06501495

Aging Alzheimer Disease

RECRUITING NA

Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population

NCT01835717

Healthy Individuals

COMPLETED

Epileptiform Activity During REM Sleep in Alzheimer's Disease

NCT03923569

Alzheimer Disease, Early Onset

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is solid neurophysiological evidence indicating that abnormal brain rhythms during sleep and noradrenergic dysfunction are core components of cognitive decline and AD onset, and their related pathophysiology. Crucially, irregularities in these neurophysiological mechanisms appear to occur in an asymptomatic and pre-symptomatic stage, but their potential to identify susceptibility for triggering neurodegeneration has yet to be established.

Thus, the possibility to identify such risk biomarkers in humans will require the acquisition of large-scale data related direct or indirect measurements of these physiological signatures. A possible key source to obtain such large-scale data related to sleep and noradrenergic function is the assessment of electroencephalographic recordings through non-obtrusive, low-cost, and reliable wearable sensors, alongside the use of advanced neuro-computational algorithms that link brain function and behavioral outcomes of LC function via pupilometry measurements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease, Early Onset

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ADAD family members, mutation carriers

asymptomatic and presymptomatic individuals

This is an observational study

Intervention Type OTHER

This is an observational study

ADAD family members, non-mutation carriers

age-matched family members (non-mutation carriers) relative to the asymptomatic/presymptomatic group

This is an observational study

Intervention Type OTHER

This is an observational study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

This is an observational study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Informed Consent as documented by signature mutation and non-mutation carriers of ADAD populations Patients diagnosed with MCI and AD

Diseases or lesions of the nervous system (acute or residual included neurological and psychiatric diseases, except for MCI and AD in the patient population) Clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) Sleep disorders, known or suspected (e.g. Insomnia, sleep apnoea, restless leg syndrome, narcolepsy, etc.) mini mental state examination (MMSE) score \> 24)

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No